sarpogrelate

structure given in first source

Also Known As:

2-(dimethylamino)-1-((2-(3-methoxyphenyl)phenoxy)methyl)ethyl hydrogensuccinate hydrochloride; MCI 9042; MCI-9042; mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride

Networked: 147 relevant articles (27 outcomes, 35 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Dicarboxylic Acids: 108
      - Succinates: 13
        sarpogrelate: 147

Experts

1.	Dhalla, Naranjan S: 6 articles (10/2012 - 01/2002)
2.	Kumamoto, Hideo: 5 articles (09/2008 - 01/2002)
3.	Fujita, Masatoshi: 4 articles (04/2008 - 08/2002)
4.	Takeda, Nobuakira: 4 articles (04/2008 - 01/2002)
5.	Kwak, Mi-Kyoung: 3 articles (01/2021 - 01/2016)
6.	Heo, Tae-Hwe: 3 articles (12/2018 - 01/2016)
7.	Park, Kyung-Yeon: 3 articles (12/2018 - 01/2016)
8.	Kim, Sang-Hyun: 3 articles (03/2016 - 12/2010)
9.	Higashi, Yukihito: 3 articles (12/2012 - 04/2007)
10.	Nishimaru, Katsuya: 3 articles (08/2009 - 01/2007)

Related Diseases

1.	Ischemia 09/01/2006 - "The findings demonstrate that sustained-release bFGF stimulated the development of collateral vessels, and additional administration of sarpogrelate produced a further improvement in hindlimb blood flow in the rabbit hindlimb ischemia model." 02/01/2013 - "This study was designed to examine the impact of combined multipotent adipose-derived stromal cells (mADSCs) and sarpogrelate treatment on aging hindlimb ischemia and the mechanism of action involved. " 04/01/2003 - "Rats were intraperitoneally injected with MCI-9042 at a dose of 3, 30 mg/kg or base at 30 min before and just after ischemia-reperfusion. " 09/01/2001 - "Sarpogrelate (50 nM-0.9 microM) was infused 10 min before ischemia as well as during the reperfusion period. " 04/01/2005 - "The protective effects of sarpogrelate (SG), a 5-HT2A antagonist, were investigated in perfused guinea-pig Langendorff hearts subjected to ischemia and reperfusion. "
2.	Albuminuria 05/01/1999 - "5. In protocol II, in the sarpogrelate treatment group (group E), albuminuria was significantly improved and both plasma levels TXB2 and urinary TXB2 excretion were significantly decreased. " 03/01/2008 - "Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy. " 11/01/2002 - "Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy." 05/01/1999 - "3. In protocol II, 10 NIDDM patients with UalbV values > 100 mg/day were divided into two groups to further confirm the effect of sarpogrelate on albuminuria: group E, the sarpogrelate treatment group (n = 5); and group F, the no treatment group (n = 5). " 04/01/2008 - "Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats. "
3.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2017 - "Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice." 03/01/2008 - "Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy. " 11/01/2002 - "Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy." 04/01/2008 - "Our results indicate that sarpogrelate improves endothelial function in rats with STZ-induced diabetes through a reduction of glomerular platelet activation and an increase in serum adiponectin concentrations and suggest that sarpogrelate is potentially useful for the treatment of diabetic nephropathy." 01/01/2021 - "Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy."
4.	Myocardial Infarction 01/01/2002 - "Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats." 09/01/2017 - "Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study." 01/01/2002 - "This study examined the effect of sarpogrelate, a 5-HT(2A) receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI). " 01/01/2004 - "Sarpogrelate has been found to have beneficial effects in peripheral vascular disease, restenosis after coronary stenting, pulmonary hypertension, acute and chronic myocardial infarction." 10/26/2021 - "A mix of bromocriptine or cabergoline with sarpogrelate diminished the level of the myocardial infarct size in the heart assessed through the TTC staining method. "
5.	Systemic Scleroderma (Systemic Sclerosis) 02/01/2006 - "Sarpogrelate hydrochloride (SH) is an antagonist of the 5-hydroxytryptamine2A (5HT2A) receptor and has been reported to be effective in the treatment of systemic sclerosis (SSc) patients with Raynaud phenomenon. " 06/01/2012 - "Eleven patients with skin ulcers and systemic sclerosis (SSc) were administrated sarpogrelate p.o. " 06/01/2012 - "Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis." 11/01/2000 - "We evaluated the effect of 12 months of 300-mg oral sarpogrelate hydrochloride (SH) once daily on the symptoms of Raynaud's phenomenon, respiratory failure and cardiac function in seven patients with systemic sclerosis. " 11/01/2000 - "Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis."

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
3.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
4.	Cilostazol (Pletal)
5.	Pravastatin (Pravachol)
6.	Epinephrine (Adrenaline)
7.	beraprost
8.	tyrosine-4-azophenyltrimethylammonium chloride (TAPT)
9.	Serotonin Antagonists
10.	Serotonin 5-HT2 Receptor Antagonists

Related Therapies and Procedures

1.	Therapeutics
2.	Heart Valve Prosthesis
3.	Injections
4.	Percutaneous Coronary Intervention
5.	Secondary Prevention